Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Dystrophin involvement in peripheral circadian SRF signalling.

Betts CA. et al, (2021), Life Sci Alliance, 4

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology.

van Westering TLE. et al, (2020), J Cachexia Sarcopenia Muscle, 11, 578 - 593

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.

Yin H. et al, (2019), Hum Mol Genet, 28

Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment.

Gait MJ. et al, (2019), Nucleic Acid Ther, 29, 1 - 12

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.

Betts CA. et al, (2019), Hum Mol Genet, 28, 396 - 406

Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice.

Walter LM. et al, (2018), Hum Mol Genet, 27, 3582 - 3597

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice.

Walter LM. et al, (2018), EBioMedicine, 31, 226 - 242

Profile of circadianly regulated metabolic genes in dystrophic heart

Betts CA. et al, (2018), NEUROMUSCULAR DISORDERS, 28, S19 - S19

PROFILE OF CIRCADIANLY REGULATED METABOLIC GENES IN DYSTROPHIC HEART

Betts CA. et al, (2018), HEART, 104, A4 - A4

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.

Blain AM. et al, (2018), PLoS One, 13

Corrigendum: Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.

Coenen-Stass AML. et al, (2016), Sci Rep, 6

Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation.

Coenen-Stass AML. et al, (2016), Hum Mol Genet, 25, 3960 - 3974

Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.

Coenen-Stass AML. et al, (2015), Sci Rep, 5

How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.

Godfrey C. et al, (2015), Hum Mol Genet, 24, 4225 - 4237

Delivery of therapeutic oligonucleotides with cell penetrating peptides.

Boisguérin P. et al, (2015), Adv Drug Deliv Rev, 87, 52 - 67

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.

Betts CA. et al, (2015), Sci Rep, 5

Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy.

van Westering TLE. et al, (2015), Molecules, 20, 8823 - 8855

Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.

Betts CA. et al, (2015), Sci Rep, 5

Delivery of therapeutic oligonucleotides with cell penetrating peptides

(2015), Advanced Drug Delivery Reviews, 87, 52 - 67

Detection and quantification of extracellular microRNAs in murine biofluids.

Roberts TC. et al, (2014), Biol Proced Online, 16

Load More

Include forthcoming?